Quick Answer
Sonoma Pharmaceuticals, Inc. reported Diluted EPS of $2.79 per share (loss) for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.79 | +73.8% |
| 2024 | -$10.63 | -599.3% |
| 2023 | -$1.52 | +20.8% |
| 2022 | -$1.92 | -125.9% |
| 2015 | -$0.85 | -257.4% |
| 2014 | $0.54 | +141.5% |
| 2013 | -$1.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.48 | +23.8% | -50.0% |
| September 30, 2025 | -$0.32 | +45.8% | +57.9% |
| June 30, 2025 | -$0.76 | +43.3% | -20.6% |
| December 31, 2024 | -$0.63 | +60.4% | -6.8% |
| September 30, 2024 | -$0.59 | +89.7% | +56.0% |
| June 30, 2024 | -$1.34 | -362.1% | +15.7% |
| December 31, 2023 | -$1.59 | -156.5% | +72.3% |
| September 30, 2023 | -$5.75 | -1642.4% | -1882.8% |
- Sonoma Pharmaceuticals, Inc. showed an increase of +73.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2013–2025 period, Sonoma Pharmaceuticals, Inc.’s diluted eps has declined by 114.6% (from $1.30 per share (loss) to $2.79 per share (loss)).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: